


Abbott India Limited  
271, Business Park, 6th Floor.  
Model Industrial Colony,  
Off Aarey Road, Goregaon (E)  
Mumbai 400063

Registered Office:  
3-4, Corporate Park,  
Sion Trombay Road,  
Mumbai 400 071, India

Tel : (91-22) 2871 7462  
Fax : (91 22) 2871 7499  
E-mail : webmaster@abbott.co.in  
Site : www.abbott.co.in  
CIN : L24239MH1944PLC007330



BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

November 28, 2016

**Scrip Code: 500488**

Dear Sir,

**Sub: Intimation under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a text of Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2016, approved by the Board of Directors at its Meeting held on Monday, November 28, 2016, along with the Limited Review Report issued by S R B C & CO. LLP, Statutory Auditors of the Company.

The Meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 1.45 pm.

Kindly acknowledge the receipt of the same.

Thank you.

Yours faithfully,  
**Abbott India Limited**

**Krupa Anandpara**  
**Company Secretary**  
**Membership No.: ACS 16536**

Encl: a/a

**Limited Review Report****Review Report to  
The Board of Directors  
Abbott India Limited**

We have reviewed the accompanying statement of unaudited financial results of Abbott India Limited ('the Company') for the quarter ended September 30, 2016 and year to date from April 1, 2016 to September 30, 2016 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not audited or reviewed the accompanying financial results and other financial information for the three months ended September 30, 2015 and the year to date period ended September 30, 2015, which have been presented solely based on the information compiled by Management.

**For S R B C & CO LLP**


ICAI Firm registration number: 324982E/E300003

Chartered Accountants

**per Ravi Bansal**  
Partner  
Membership No.: 49365

Place: Mumbai


Date: November 28, 2016



Statement of Unaudited Results for the Quarter and Half year ended September 30, 2016

(Rs. in Lakhs except earnings per share)

	Particulars	Quarter ended	Quarter ended	Quarter ended	Six Months ended	Six Months ended
		September 30, 2016	June 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
<b>1</b>	<b>Income from Operations</b>					
	(a) Sales (Inclusive of Excise Duty)	721,14	731,33	640,26	1452,47	1271,00
	(b) Other Operating Income	8,29	6,79	8,72	15,08	15,24
	<b>Total Income from Operations</b>	<b>729,43</b>	<b>738,12</b>	<b>648,98</b>	<b>1467,55</b>	<b>1286,24</b>
<b>2</b>	<b>Expenses</b>					
	(a) Cost of Materials Consumed	95,97	71,85	70,28	167,82	151,48
	(b) Purchase of Stock-in-Trade	432,72	365,92	301,18	798,64	514,15
	(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(98,99)	(18,37)	(5,64)	(117,36)	60,26
	(d) Employee Benefits Expense	86,85	85,81	86,84	172,66	172,67
	(e) Depreciation and Amortization Expense	4,08	4,16	3,42	8,24	6,78
	(f) Other Expenses	106,89	127,51	109,78	234,40	206,63
	<b>Total Expenses</b>	<b>627,52</b>	<b>636,88</b>	<b>565,86</b>	<b>1264,40</b>	<b>1111,97</b>
<b>3</b>	<b>Profit from operations before Other Income, Finance Costs (1-2)</b>	<b>101,91</b>	<b>101,24</b>	<b>83,12</b>	<b>203,15</b>	<b>174,27</b>
<b>4</b>	<b>Other Income</b>	<b>14,35</b>	<b>13,94</b>	<b>13,10</b>	<b>28,29</b>	<b>25,62</b>
<b>5</b>	<b>Profit before Finance Costs (3+4)</b>	<b>116,26</b>	<b>115,18</b>	<b>96,22</b>	<b>231,44</b>	<b>199,89</b>
<b>6</b>	<b>Finance Costs</b>	<b>1</b>	<b>2</b>	<b>41</b>	<b>3</b>	<b>44</b>
<b>7</b>	<b>Profit before tax (5-6)</b>	<b>116,25</b>	<b>115,16</b>	<b>95,81</b>	<b>231,41</b>	<b>199,45</b>
<b>8</b>	<b>Tax Expense</b>	<b>41,23</b>	<b>41,15</b>	<b>34,65</b>	<b>82,38</b>	<b>70,98</b>
<b>9</b>	<b>Net Profit for the Period (7-8)</b>	<b>75,02</b>	<b>74,01</b>	<b>61,16</b>	<b>149,03</b>	<b>128,47</b>
<b>10</b>	<b>Other Comprehensive Income (after Tax)</b>					
	- Items that will not be classified to Profit or Loss	-	-	(25)	-	(50)
	- Items that will be classified to Profit or Loss	-	-	-	-	-
	Total Other Comprehensive Income (after Tax)	-	-	(25)	-	(50)
<b>11</b>	<b>Total Comprehensive Income for the period (9+10)</b>	<b>75,02</b>	<b>74,01</b>	<b>60,91</b>	<b>149,03</b>	<b>127,97</b>
<b>12</b>	<b>Paid-up Equity Share Capital (Face Value Rs.10 per Equity Share)</b>	<b>21,25</b>	<b>21,25</b>	<b>21,25</b>	<b>21,25</b>	<b>21,25</b>
<b>13</b>	<b>Earnings Per Share (EPS) (of Rs. 10/- each) (not annualised):</b>					
	a. Basic	35.30	34.83	28.66	70.13	60.22
	b. Diluted	35.30	34.83	28.66	70.13	60.22

SIGNED FOR IDENTIFICATION  
BY  
  
S R B C & CO LLP  
MUMBAI

Statement of Assets and Liabilities

(Rs. in Lakhs)	
As at	
September 30, 2016	
Unaudited	
<b>ASSETS</b>	
<b>Non-Current Assets</b>	
Property, plant and equipment	103,25
Capital work-in-progress	5,50
Other Intangible assets	1,99
Intangible assets under development	1,54
Financial Assets	
Loans	23,84
Others	3,04
Deferred Tax Assets (Net)	11,21
Other Non-Current Assets	20,40
<b>Total Non-Current Assets</b>	<b>170,77</b>
<b>Current Assets</b>	
Inventories	476,62
Financial Assets	
Trade Receivables	177,30
Cash and Cash equivalents	216,09
Bank Balances other than above	656,06
Loans	20,51
Other Financial Assets	12,43
Current Tax Assets (Net)	13,01
Other Current Assets	50,00
<b>Total Current Assets</b>	<b>1622,02</b>
<b>TOTAL ASSETS</b>	<b>1792,79</b>
<b>EQUITY AND LIABILITIES</b>	
<b>Equity</b>	
Share Capital	21,25
Other Equity	1235,27
<b>Total Equity</b>	<b>1256,52</b>
<b>Non-Current Liabilities</b>	
Provisions	46,75
<b>Total Non-Current Liabilities</b>	<b>46,75</b>
<b>Current Liabilities</b>	
Financial Liabilities	
Trade Payables	328,24
Other Financial Liabilities	35,45
Other current liabilities	39,22
Provisions	65,57
Current Tax Liabilities (Net)	21,04
<b>Total Current Liabilities</b>	<b>489,52</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1792,79</b>

Notes :

- 1 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2016, the Company has for the first time adopted Ind AS with a transition date of April 1, 2015. The impact of transition has been accounted for in opening reserves and the comparative period results have been restated accordingly. These however have not been subjected to limited review or audit. The management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of the Company's affairs. The opening balance sheet as of April 1, 2015 and the results for the subsequent periods would get finalised along with the annual financial statements for the year ending March 31, 2017.
- 2 The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on November 28, 2016.
- 3 The Company operates in single reportable business segment i.e. "Pharmaceuticals" and single reportable geographical segment i.e. "Within India".
- 4 The format for un-audited quarterly and half yearly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.

**SIGNED FOR IDENTIFICATION**  
**BY**  
  
**S R B C & CO LLP**  
**MUMBAI**

5 The reconciliation of net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with IND AS is given below :

	(Rs. in Lakhs)	
	Quarter ended September 30, 2015	Six Months ended September 30, 2015
<b>Net Profit under Previous GAAP</b>	<b>61,70</b>	<b>130,26</b>
<b>Add/(Less) : Adjustments of</b>		
Cost of employee share based payments	(1,73)	(3,44)
Actuarial loss on employee defined benefit funds recognized in Other Comprehensive Income	38	76
Physicians samples written off	1,65	1,76
Others	1	1
Deferred Tax impact on IND AS adjustments	(85)	(88)
<b>Net Profit for the period under IND AS</b>	<b>61,16</b>	<b>128,47</b>
Other Comprehensive Income (after Tax)	(25)	(50)
<b>Total Comprehensive Income for the period</b>	<b>60,91</b>	<b>127,97</b>

6 Figures for the previous period have been regrouped/reclassified wherever considered necessary.

Place : Mumbai  
Date : November 28, 2016

*[Handwritten signature]*



For and on behalf of the Board of Directors of  
Abbott India Limited

*[Handwritten signature]*  
Mr Ambati Venu  
Managing Director  
DIN : 07614849